Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP

Trial ID: NCT05562960

Interventional - Phase Unknown - Completed

Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody

Conditions

• Amyotrophic Lateral Sclerosis
• Plasmapheresis

Interventions

• Plasmapheresis

Eligibility

Inclusion criteria

• 1. Patients with amyotrophic lateral sclerosis (ALS) at the age more than 20 years and having plasma anti-NRIP autoantibody.
• 2. Agree to receive plasmapheresis intervention.
• 3. Agree to participate in the trial and receive serial examinations and follow up.

Exclusion criteria

• 1. Patients without plasma anti-NRIP autoantibody.
• 2. Patients requiring permanent ventilator support for ALS progression.
• 3. Not able to receive plasmapheresis or trial-related examinations.
• 4. Under pregnancy.
• 5. Blood fibrinogen level less than 50 mg/dl.
• 6. Specific ALS subtypes, including primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, or flail leg syndrome.

Sponsor

National Taiwan University Hospital

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows